60 Degrees Pharmaceuticals (SXTP) News Today $1.39 +0.07 (+5.30%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Weiss Ratings Reiterates "Sell (E+)" Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)July 31, 2025 | americanbankingnews.com60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingJuly 16, 2025 | globenewswire.com60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionJuly 15, 2025 | globenewswire.comSXTP - 60 Degrees Pharmaceuticals Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comM60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthApril 8, 2025 | globenewswire.com60 Degrees Pharmaceuticals, Inc.April 4, 2025 | uk.investing.com60 Degrees Pharmaceuticals announces 1-for-5 reverse stock splitFebruary 20, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitFebruary 20, 2025 | globenewswire.com60 Degrees says FDA does not object to tafenoquine import planFebruary 11, 2025 | markets.businessinsider.comSixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®February 11, 2025 | globenewswire.comInsiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55February 9, 2025 | finance.yahoo.com60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 6, 2025 | globenewswire.com60 Degrees prices 1.5M shares at 71.5c in registered direct offeringFebruary 5, 2025 | markets.businessinsider.com60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 5, 2025 | globenewswire.com60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.com60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 29, 2025 | markets.businessinsider.com60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisJanuary 28, 2025 | globenewswire.com60 Degrees Pharmaceuticals enrolls first patient in tafenoquine studyJanuary 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisJanuary 8, 2025 | globenewswire.com60 Degrees signs patent license deal with Tufts Medical, says H.C. WainwrightDecember 25, 2024 | markets.businessinsider.com60 Degrees, Tufts Medical Center announces patent license agreementDecember 24, 2024 | finance.yahoo.comSixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionDecember 23, 2024 | globenewswire.com60 Degrees expands tafenoquine clinical trial to Brigham and Women’s HospitalDecember 12, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)December 12, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalDecember 11, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's HospitalDecember 11, 2024 | globenewswire.comInsider Buying: 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Buys 17,549 Shares of StockDecember 10, 2024 | insidertrades.com60 degrees pharmaceuticals CEO Geoffrey Dow acquires $6,367 in stockNovember 23, 2024 | investing.com60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNovember 14, 2024 | globenewswire.com60 Degrees (NASDAQ:SXTP) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.com60 Degrees (NASDAQ:SXTP) Stock, Short Interest ReportOctober 4, 2024 | benzinga.com60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchOctober 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 7, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 4, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsAugust 28, 2024 | globenewswire.com60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 18, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsAugust 14, 2024 | globenewswire.comShould You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?August 12, 2024 | msn.comWhy Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?August 12, 2024 | investorplace.com Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address SXTP Media Mentions By Week SXTP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼-1.000.38▲Average Medical News Sentiment SXTP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼01▲SXTP Articles Average Week Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVOK News Today TLPH News Today CELZ News Today NKGN News Today KPRX News Today APM News Today PRTG News Today PLRZ News Today CDIO News Today ALZN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts